JE vaccine also should be considered for shorter-term (e.g., <1 month) travelers with an increased risk for JE on the basis of planned travel duration, season, location, activities, and accommodations and for travelers to JE-endemic areas who are uncertain about their specific travel duration, destinations, or activities. JE vaccine is recommended for persons moving to a JE-endemic country to take up residence, longer-term (e.g., ≥1 month) travelers to JE-endemic areas, and frequent travelers to JE-endemic areas. The decision about whether to vaccinate should be individualized and consider the 1) risks related to the specific travel itinerary, 2) likelihood of future travel to countries where JE is endemic, 3) high morbidity and mortality of JE, 4) availability of an effective vaccine, 5) possibility (but low probability) of serious adverse events after vaccination, and 6) the traveler’s personal perception and tolerance of risk. For some persons who might be at increased risk for JE, the vaccine can further reduce the risk for infection. All travelers to countries where JE is endemic should be advised to take precautions to avoid mosquito bites to reduce the risk for JE and other vectorborne diseases. Factors that increase the risk for JE virus exposure include 1) traveling for a longer period 2) travel during the JE virus transmission season 3) spending time in rural areas 4) participating in extensive outdoor activities and 5) staying in accommodations without air conditioning, screens, or bed nets. However, some travelers are at increased risk for infection on the basis of their travel plans. Most travelers to countries where the disease is endemic are at very low risk for JE. Food and Drug Administration (FDA) licensed JE-VC for use in persons aged ≥17 years in 2013, licensure was extended to include children aged ≥2 months. Inactivated Vero cell culture–derived JE vaccine (Ixiaro ) is the only JE vaccine that is licensed and available in the United States. Approximately 20%–30% of patients die, and 30%–50% of survivors have neurologic, cognitive, or behavioral sequelae. JE occurs throughout most of Asia and parts of the western Pacific. JE virus, a mosquitoborne flavivirus, is the most common vaccine-preventable cause of encephalitis in Asia. The report summarizes the epidemiology of JE, describes the JE vaccine that is licensed and available in the United States, and provides recommendations for its use among travelers and laboratory workers. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). travelers and laboratory workers (Fischer M, Lindsey N, Staples JE, Hills S. This report updates the 2010 recommendations from the CDC Advisory Committee on Immunization Practices (ACIP) regarding prevention of Japanese encephalitis (JE) among U.S.

Human japanese trial vs full version